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Abstract
PRL oncoproteins are phosphatases overexpressed in numerous types of human cancer. Elevated 
levels of PRL associate with metastasis and poor clinical outcomes. In principle, PRL 
phosphatases offer appealing therapeutic targets, but they remain underexplored due to the lack of 
specific chemical probes. In this study, we address this issue by exploiting a unique property of 
PRL phosphatases, namely, that they may function as homotrimers. Starting from a sequential 
structure-based virtual screening and medicinal chemistry strategy, we identified Cmpd-43 and 
several analogs which disrupt PRL1 trimerization. Biochemical and structural analyses 
demonstrate that Cmpd-43 and its close analogs directly bind the PRL1 trimer interface and 
obstruct PRL1 trimerization. Cmpd-43 also specifically blocks the PRL1-induced cell proliferation 
and migration through attenuation of both ERK1/2 and Akt activity. Importantly, Cmpd-43 exerted 
potent anticancer activity both in vitro and in vivo in a murine xenograft model of melanoma. Our 
results validate a trimerization-dependent signaling mechanism for PRL and offer proof-of-
concept for trimerization inhibitors as candidate therapeutics to treat PRL-driven cancers
Introduction
Reversible and coordinated protein tyrosine phosphorylation is central to diverse signal 
pathways regulating cell growth, migration and survival. Disturbance of the normal pattern 
of tyrosine phosphorylation, due to perturbed balance between the activities of protein 
tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), causes abnormal cell 
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signaling and has been linked to the etiology of many human diseases including cancer (1). 
Thus there is vast interest in targeting dysfunctional pathways driven by aberrant tyrosine 
phosphorylation for therapeutic interventions. Notable success has been achieved by 
targeting the PTKs, as shown by the more than two-dozen small molecule inhibitors already 
in the clinic (2). However, resistance to kinase inhibitor treatments prevents durable 
responses. Therefore, there is heightened interest to modulate disease progression at the 
level of PTPs.
The PRL (phosphatase of regenerating liver) phosphatases constitute a unique group of 
PTPs, with three closely related members (PRL1, 2 and 3) (3-6). Unlike other PTPs, the 
PRLs function as positive signal transducers capable of activating both ERK1/2 (7-11) and 
Akt (12-15), two of the major pathways that are aberrantly up-regulated in cancer (16, 17). 
PRL1 was initially identified as an immediate early gene induced during liver regeneration 
upon partial hepatectomy (18). Subsequent studies found that exogenous expression of PRLs 
accelerates cell proliferation and anchorage-independent growth (7, 18-21). Constitutive 
PRL expression also promotes cell migration and invasion (7, 8, 11, 22-25). Moreover, PRL 
overexpressing cells form tumors with high metastatic potential when injected into mice (9, 
22, 23, 26), whereas PRL knockdown reduces cell proliferation and migration as well as 
tumorigenesis in vivo (9, 11, 25, 27-30) Most significantly, PRL level is elevated in human 
cancers of colon (31, 32), liver (23, 33), ovarian (27, 34), prostate (35), gastric (36, 37), 
pancreatic (13), and breast (9, 38), as well as in melanoma (20, 39), multiple myeloma (40) 
and acute myeloid leukemia (41, 42), and PRL overexpression strongly correlates with late 
stage metastasis and poor clinical outcomes. Taken together, the data implicate PRLs as 
novel molecular markers and therapeutic targets for metastatic cancers. Consequently, PRLs 
have garnered considerable interest for drug discovery (6). Unfortunately, the rather flat PRL 
active site and its structural similarity to other members of the PTP family present 
significant challenge for PRL inhibitor design. Indeed, reported active site directed PRL 
inhibitors are neither sufficiently potent nor selective, and so are not suitable for in vivo 
pharmacological study and therapeutic development (6).
We describe a novel approach to inhibit PRL function by targeting a unique structural and 
regulatory property of the PRLs. One of the most striking features of PRL1 is that it exists as 
a trimer in the crystalline state and has a high propensity to form trimer in solution and 
inside the cell (8, 10, 43, 44). Moreover, trimer formation is essential for PRL1-mediated 
cell growth and migration, suggesting that small molecules targeting the trimeric interface of 
PRLs could potentially have therapeutic value (8). To capitalize on these findings, we used a 
computer-based virtual screen to search the available chemical databases for compounds 
capable of disrupting PRL trimerization. Biochemical and structural analyses demonstrate 
that Cmpd-43 and its close analogs bind the PRL1 trimer interface and block PRL1 
trimerization. Cmpd-43 also specifically abrogates the PRL1-induced cell proliferation and 
migration through attenuation of both ERK1/2 and Akt activity. Importantly, Cmpd-43 
exhibits excellent anti-cancer activity both in vitro and in a xenograft mouse model of 
melanoma. The study provides pharmacological validation that trimerization is important for 
PRL1 function and targeting PRL trimerization is a viable approach for therapeutic 
development.
Bai et al. Page 2
Cancer Res. Author manuscript; available in PMC 2017 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Materials and Methods
Materials
Anti-HA, anti-tubulin and anti-GAPDH antibodies were purchased from Santa Cruz 
Biotechnology. Anti-ERK1/2, anti-pERK1/2 (Thr202/Tyr204), anti-Akt, anti-pAkt (Ser473) 
and anti-LSD1 antibodies were obtained from Cell Signaling. Dulbecco's modified Eagle's 
medium (DMEM), fetal bovine serum, penicillin, and streptomycin were from Invitrogen. 
HEK293, MeWo and MCF7 cell lines were purchased directly from ATCC between 2008 
and 2015. The ATCC cell lines were characterized by short tandem repeat (STR) DNA 
profiling. MCF10A cell was received as a gift from Dr. Mircea Ivan's lab in Indiana 
University School of Medicine, and was authenticated by morphology. All cell lines were 
passaged for fewer than 6 months after resuscitation.
Virtual screening
Asinex and ChemBridge subsets in ZINC (45) database were downloaded from ZINC 
website (http://zinc.docking.org) and used for virtual screening. The monomer B in PRL1 
trimer structure (PDBID: 1ZCK) (44) was used as receptor, and the coordinates were 
retrieved from the Protein Data Bank. The DOCK6.2 program (46) was used for rigid 
docking to generate a potential subset of molecules binding at PRL1 trimer interface, and 
then AutoDock4.01 software (47) was used for flexible docking to get the most potent hits.
In the first stage docking, the structure of monomer B was processed using the “Dock Prep” 
module in UCSF CHIMERA, then the docking region was defined through a standard 
pipeline of running dms, sphgen, sphere_selector and showbox program, and the energy 
scoring values were calculated by grid program. About 560,000 small molecules 
(downloaded in 28 mol2 files, ∼20,000 molecules in each file) were submitted to the 
dock6.mpi program to perform docking calculations simultaneously. During each docking, 
the small molecule was positioned with 1,000 orientations, the lowest interaction energy and 
corresponding conformation was recorded. All ligands in each mol2 file were ranked 
according to their lowest interaction energy, and the top 2,000 were kept for the second stage 
docking, thus 56,000 (2,000 × 28) molecules were picked out for next stage screening.
In the second stage docking, the structure of monomer B was processed in 
AutoDockTools1.4 software, Gasteiger charge was added and non-polar hydrogens were 
merged. The docking area was designated around the BA- or BC-interface, and the energy 
grids of 51 × 51 × 73 points with 0.375 Å spacing on each axis were calculated for 17 atom 
types (H, HD, HS, C, A, N, NA, NS, OA, OS, F, P, SA, S, Cl, Br and I), as well as the 
electrostatic and desolvation potential using autogrid4 program; On the other hand, each 
ligand structure was used to generate pdbqt and dpf files using prepare_ligand4.py and 
prepare_dpf4.py scripts. Based on these prepared files, molecular docking was carried out in 
autodock4 program as follows: 10 separate docking runs were performed for each ligand. In 
each docking run, the optimal binding conformation was achieved by Lamarckian Genetic 
Algorithm with Local Search (LGALS) method. After all ligands were docked, the lowest 
binding free energy of each ligand was extracted and ranked, and hit molecules were picked 
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out through binding free energy comparisons, structure similarity analyses and binding mode 
inspections.
Cell culture and transfection
HEK293, MeWo, and MCF7 cells were grown in DMEM supplemented with 10% fetal 
bovine serum, penicillin (50 units/mL), and streptomycin (50 μg/mL) in a 37°C incubator 
containing 5% CO2. MCF10A cells were grown in MEBM medium supplemented with 
MEGM Single Quots and 100 ng/mL cholera toxin (Lonza, Basel, Switzerland). HEK293 
cells were seeded at 40% confluence in antibiotic-free medium and grown overnight. 
Transfection was performed using Lipofectamine 2000 from Invitrogen according to the 
manufacturer's recommendations.
Wound healing assay
Cells were grown to 90% confluence in a 12-well plate at 37 °C in an atmosphere of 5% 
CO2. A wound was created by scratching cells with a sterile 200 μL pipette tip. Cells were 
washed with PBS to remove the floating cells, and then treated with fresh medium 
containing 20 μM compound or DMSO. The wounds were photographed at 0 hour and 24 
hours under ×10 magnitude microscope. Wound healing magnitude was quantified by 
measuring the relative wound closure compared with control cells at 24 hours.
MTT assay
Cells were seeded in a 96-multiwell plate (3000 cells/well) containing DMEM, 10% fetal 
bovine serum at 37 °C in an atmosphere of 5% CO2 overnight. Cells were then treated with 
various concentrations of compounds or DMSO for 24 and 48 hours. Cell proliferation was 
then determined by MTT assay as described previously (8) using a multiwall 
spectrophotometer. Data are presented as relative proliferation rate compared with control 
cells.
Cell migration assay
Cell migration was determined as described previously (10) with some modifications. The 
assay was performed with Transwells (6.5 mm diameter; 8 μM pore size polycarbonate 
membrane) obtained from Corning (Costar, Acton, MA). Cells (3.75 × 105) in 1.5 mL of 
serum-free medium were placed in the upper chamber, whereas the lower chamber was 
loaded with 2.5 mL of medium containing 10% FBS. Cells were then treated with 10 μM of 
different compounds as indicated. After 24 hour incubation (37 °C, 5% CO2), the total 
number of cells that had migrated into the lower chamber was counted with a 
hemacytometer. Data are presented as relative migration rate compared with control cells. 
Cell motility of MeWo cells was also measured using live-cell imaging. 5×103/well of 
MeWo cells were seeded in a 96-well plate for overnight and then treated with 5 μM of 
Cmpd-43 for 4 hours. 1μg/mL of Hoechst 33342 was used to label the nuclei, and Thermo 
Scientific ArrayScan XTI Live High Content Platform was then used for live-cell tracking to 
measure the motility in the presence of Cmpd-43. Motility of the cells was assessed over 6 h 
and image data were collected every 30 min.
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Animal experiments
NSG (NOD/scid/IL2Rgnull) mice were purchased from In Vivo Therapeutics Core at Indiana 
University Simon Cancer Center. Experiments on mice were carried out in accordance with 
the regulations of The Institutional Animal Care and Use Committees at Indiana University. 
All mice were housed under pathogen-free conditions in the animal facility and received 
autoclaved water and food. 10-12 weeks old NSG mice were used in the study. MeWo cells 
were suspended in phosphate-buffered saline (PBS) at 8×107 cells/ml. A total of 8×106 cells 
(100 μl) were subcutaneously implanted into both left and right flank (n=24) using a 27-
gauge needle. Once the tumor volume reaches 200 mm3, daily intraperitoneal injection of 
either control or 30 mg/kg Cmpd-43 was performed, and the tumor growth was monitored 
for 3 weeks. Tumor volume was calculated using the formula V=(W2×L)/2 for caliper 
measurements. Mice were sacrificed after injection for 21 days, and organs were collected 
for immunohistological and biochemical analysis.
Statistics
For cell-based proliferation, migration and wound healing assays, the Student's t test was 
used to measure the significance. For MeWo cell xenograft tumors, tumor volumes at 
different time and final tumor weights were compared using the Student's t test. In 
comparing the mRNA level of PRLs in human normal skin and melanoma samples, 
Student's t test was used assess the significance of differences between groups. Survival 
analysis was performed according to the Kaplan-Meier method and the log-rank test, a p-
value of less than 0.05 was considered statistically significant.
Results and Discussion
Identification of small molecule PRL1 detrimerizers
Given the functional requirement of PRL trimerization, disruption of PRL trimerization was 
proposed as a potential therapeutic approach for PRL-based drug discovery (8), but this 
strategy has not been validated with pharmacologic approaches. As revealed by the 
homotrimeric PRL1 crystal structure (44), each PRL1 monomer (e.g. monomer B) has two 
dimer interfaces, namely the BA- (residues from 125 to 150) and BC-interfaces (residues 
from 11 to 18, 36 to 41, and 92 to 98), which are 18 and 19 Å away from the active site 
Cys104 in the catalytic P-loop C104VAGLGR110 (Figure 1A). To discover small molecules 
capable of blocking PRL1 trimerization, we used structure-based virtual screening to 
identify compounds that bind to the dimer interfaces in each PRL1 monomer. We employed 
a sequential screening strategy, starting with rigid docking in DOCK6.2 (46) to sample a 
total of 560,000 compounds (Asinex and ChemBridge subsets in the ZINC database) (45) to 
each dimer interface and score protein–ligand complexes based on the calculated interaction 
energies, which was followed by flexible docking in AutoDock4.01 (47) to analyze the top 
10% hits obtained from rigid docking (Figure 1B). This process led to the selection of 100 
top-ranked compounds for each interface. Upon further binding mode verification and 
structural similarity analyses, 56 structurally diverse compounds were purchased for further 
experimental evaluation.
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The ability of the 56 compounds to disrupt PRL1 trimerization was initially assessed by in 
vitro cross-linking experiments using recombinant PRL1 protein (44). Ten out of the 56 
compounds exhibited significant activity in blocking PRL1 trimerization. To further confirm 
the efficiency of these compounds to disrupt PRL1 trimer formation, we also evaluated them 
in an in vivo cell-based cross-linking assay. HA-tagged PRL1 expressing HEK293 cells 
were treated with the compounds, fixed with 1% formaldehyde, and the HA-tagged PRL1 
was immunoprecipitated with HA antibodies, analyzed by SDS-PAGE and visualized by 
immunoblotting with anti-HA antibodies. As shown in Figure 1C, the top three compounds, 
Cmpd-3, Cmpd-26 and Cmpd-43, significantly decreased PRL1 trimer formation inside the 
cell, with Cmpd-43 being the most potent PRL1 detrimerizer (Figure 1D). Importantly, 
Cmpd-43 at 20 μM did not inhibit the phosphatase activity of PRL1 as well as a large panel 
of PTPs including receptor-like PTPs, PTPμ, PTPε, LAR, PTPσ and PTPγ, cytosolic PTPs, 
PTP1B, Lyp, SHP1, PTPH1, HePTP, STEP, and PEZ, the dual specificity phosphatase VHR, 
VHZ, MKP5, CDC14A, and the low molecular weight PTP.
Given that PRL1 trimerization is essential for the PRL1 mediated cell proliferation and 
migration (8), Cmpd-43 is expected to suppress both cellular processes if it disrupts PRL1 
trimerization inside the cell. To test this hypothesis, we determined the effect of Cmpd-43 on 
cell proliferation and migration in PRL1 expressing HEK293 cells. As expected, Cmpd-43 
inhibited PRL1 induced cell proliferation in a dose dependent manner (Figure 1E). In 
addition, Cmpd-43 also markedly delayed the wound closure induced by PRL1 
overexpression (Figure 1F). To delineate the structural features of Cmpd-43 important for 
inhibiting PRL1 mediated cellular processes, a series of Cmpd-43 derivatives were either 
purchased (Analogs 1 to 4) or synthesized (Analogs 5 to 7) (Figure 2A). As shown in Figure 
2B&C, Analog-3 displayed similar efficacy as Cmpd-43 in attenuating PRL1 induced cell 
proliferation and migration, while Analogs 2 and 4-7 appeared slightly less effective than 
Cmpd-43. Interestingly, Analog-1 exerted no effect on either cell proliferation or migration, 
suggesting that the iminomethyl-aromatic moiety, which is missing in Analog-1, is critical 
for the inhibitory activity of Cmpd-43 and the other 6 analogs. Collectively, through a two-
stage virtual screening strategy, biochemical and cell based evaluation, and a limited 
structure and activity analysis, we identified Cmpd-43 and several analogs as potential 
disruptors of PRL1 trimerization. We also found a structurally related but inactive Analog 1, 
which could serve as a negative control in mechanistic studies.
Cmpd-43 specifically blocks PRL1 mediated signaling, cell proliferation and migration
Before Cmpd-43 can be used as a chemical probe to address PRL1's roles in normal 
physiology and in cancer and serve as a lead for therapeutic development, it is important to 
establish whether Cmpd-43 exerts its effect inside the cell through disruption of PRL1 
trimerization and inhibition of PRL1-mediated signaling. To this end, we first compared the 
effect of Cmpd-43 and its inactive Analog-1 on PRL1 trimerization. As shown in Figure 3A, 
Cmpd-43 effectively blocked PRL1 trimerization in HEK293 cells while at the same 
concentration Analog-1 had no effect, consistent with its lack of inhibition in PRL1 
mediated cell proliferation and migration (Figure 2B&C). To further evaluate the specificity 
of Cmpd-43, we utilized a trimerization deficient mutant PRL1/G97R, which is incapable of 
promoting cell growth and migration (8). Thus Cmpd-43 would not be expected to affect the 
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growth and migration of PRL1/G97R expressing cells if its main mode of action is 
disrupting PRL1 trimerization. We first confirmed that PRL1/G97R was defective in trimer 
formation (Figure 3B). We also confirmed that while ectopic expression of PRL1 increased 
both cell proliferation and migration, the rates for the PRL1/G97R cells were similar to 
those of the vector control cells (Figure 3C&D), again validating the functional importance 
of PRL1 trimerization. We then measured the effect of Cmpd-43 and Analog-1 on the 
proliferation and migration of both wild-type PRL1 and PRL1/G97R expressing cells. As 
expected, treatment with Cmpd-43, but not Analog-1, attenuated PRL1-induced cell 
proliferation in a dose-dependent manner, while neither Analog-1 nor Cmpd-43 had any 
effect on PRL1/G97R expressing cell proliferation (Figure 3C). Similarly, Cmpd-43, but not 
Analog-1, was capable of reducing wild-type PRL1 induced cell migration, whereas neither 
Cmpd-43 nor Analog-1 was able to alter the cell migration behavior of the PRL1/G97R 
expressing cells (Figure 3D). Finally, we evaluated Cmpd-43 in mouse embryo fibroblast 
(MEF) derived from either wild-type or PRL1 deficient mice. As expected, Cmpd-43 
preferentially inhibited wild-type over PRL1-/- MEF cells (Supplemental Figure 1), 
indicating that Cmpd-43 exerted its anti-proliferative activity through blocking PRL1 
trimerization.
PRL1 promotes cell proliferation and migration through activation of ERK1/2 and Akt 
pathways (8, 13, 24). To delineate the biochemical mechanism by which Cmpd-43 exerts its 
inhibitory activity on cell growth and migration, we analyzed the effect of Cmpd-43 and 
Analog-1 on ERK1/2 and Akt activity in both wild-type PRL1 and the trimerization 
impaired PRL1/G97R mutant expressing cells. Consistent with the results from the 
phenotypic assays, expression of PRL1 increased ERK1/2 and Akt activity by 3.4 and 2.5-
fold, respectively, whereas the activation status of ERK1/2 and Akt in PRL1/G97R cells was 
similar to that of the vector control cells (Figure 3E). As expected, Cmpd-43 effectively 
abrogated the PRL1-induced ERK1/2 and Akt activation whereas the negative control 
Analog-1 had no effect on ERK/1/2 and Akt activity. In line with PRL1/G97R being a loss 
of function mutant, neither Cmpd-43 nor Analog-1 had any effect on ERK1/2 and Akt 
signaling in PRL1/G97R cells. Collectively, these mechanistic studies provide additional 
strong evidence that Cmpd-43 inhibits PRL1-mediated cellular signaling as well as cell 
proliferation and migration by blocking PRL1 trimerization.
Analog-3 binds to the PRL1 trimer interfaces and blocks PRL1 trimerization
To provide direct evidence that Cmpd-43 binds to the PRL1 trimer interfaces and to 
determine the molecular basis of PRL1 detrimerization by Cmpd-43, we sought to co-
crystallize PRL1 with Cmpd-43 as well as Analog-3. We obtained co-crystals of PRL1 
bound with Analog-3. The 3D structure of PRL1•Analog-3 complex was solved by 
molecular replacement using monomer A in the PRL1 trimer structure (PDBID: 1ZCK) (44) 
as a search model and refined to 1.90 Å resolution. The final atomic model encompasses 
residues 4-160 of PRL1 and the intact Analog-3, which is unambiguously identified by the 
unbiased Fo-Fc omit density map (Figure 4A). The details of data collection and structure 
refinement are summarized in Table 1. The complex structure belongs to the C2221 space 
group with one PRL1 molecule per asymmetric unit. Remarkably, while a homotrimeric 
arrangement was always observed in previous crystal structures of wild-type PRL1 (43, 44), 
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the PRL1/C104S mutant in complex with sulfate in the active site (44), and PRL1 in 
complex with a peptide ligand (10), the PRL1•Analog-3 complex crystallized as a monomer. 
The overall structure of PRL1•Analog-3 is quite similar to the initial search model used for 
molecular replacement. PRL1 adopts a compact α+β structure comprising a central five-
stranded β sheet surrounded by four α helixes on one side and two α helixes on the other 
side (Figure 4A). The PTP signature motif (C104VAGLGR110) forms a loop (P-loop) 
between β5 and α4 located at the base of the active site pocket. The binding site for 
Analog-3 is situated at the backside of the PRL1 active site, which is defined by residues 
within the α5 helix, α4-α5 loop, β1-β2 hairpin and the C-terminus (Figure 4A). 
Interestingly, residues involved in binding Analog-3 come from both the BC- and BA-dimer 
interfaces in the resolved complex crystal structure, with the majority of the contact area in 
the BC-interface (Figure 4B).
Figure 4C shows the detailed interactions between PRL1 and Analog-3. The dimethyl-
isoindoline moiety is placed within a hydrophobic pocket defined by Tyr14, Met124, Phe132 
and the aliphatic carbon atoms in Asp128. Specifically, the two methyl groups interact with 
Asp128 and Phe132 respectively, while the isoindoline moiety makes contacts with Tyr14, 
Met124 and Phe132. The adjacent benzohydrazide motif has several van der Waals contacts 
with residues Thr13, Tyr14 and Lys15, and the oxygen atom provides an additional polar 
interaction with terminal amine of Lys15. The furan ring extends into a cavity constituted by 
Lys15, Asn16 and Arg159, making van der Waals interactions with these residues as well as 
a polar interaction between the oxygen atom and the side chain of Asn16.
To further substantiate the molecular interactions between PRL1 and Analog-3, we mutated 
Tyr14 and Phe132, which have strong hydrophobic contacts with Analog-3 (Figure 4C). 
Analyses of the buried surface area in the dimer interfaces indicated that these two residues 
make very limited, if any, contribution to PRL1 trimerization. Thus we predicated that 
substitutions at Tyr14 and Phe132 would weaken the interaction between PRL1 and 
Analog-3/Cmpd-43, without interference with PRL1 trimerization. As expected, 
replacement of Tyr14 and Phe132 by an Ala had no effect on PRL1 trimerization and PRL1-
mediated cell migration (Figure 4D&E). Importantly, the PRL1/Y14A and PRL1/F132A 
mutants were resistant to Cmpd-43 treatment. Indeed, while Cmpd-43 blocked wild-type 
PRL1 trimerization as well as PRL1-mediated cell migration, it failed to inhibit PRL1/Y14A 
and PRL1/F132A trimer formation and had little effect on PRL1/Y14A or PRL1/F132A 
mediated cell migration (Figure 4D&E). These results are in complete agreement with the 
structural observations that residues Tyr14 and Phe132 are involved in binding Analog-3. 
Taken together, the structural and mutagenesis data provide direct evidence that Analog-3 
and Cmpd-43 bind at the PRL1 trimer interface and prevents PRL1 trimerization.
PRL1 detrimerizer Cmpd-43 exhibits anti-cancer activity
As mentioned in the introduction, PRLs are overexpressed in many tumor cell lines. To 
investigate the clinical relevance of PRL overexpression and tumor progression, we analyzed 
the Gene Expression across Normal and Tumor tissue (GENT) database, a publicly available 
microarray dataset containing more than 34,000 human cancer and normal samples (48). We 
found that samples from melanoma patients (n=302) had significantly higher PRL1 and 
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PRL2 mRNA expression compared to normal skin samples (n=141) (Figure 5A&B). To 
further evaluate the significance of PRL1 overexpression in predicting survival in patients 
with melanoma, we analyzed The Cancer Genome Atlas (TCGA) skin cutaneous melanoma 
dataset. Consistent with the oncogenic role of PRL1 in human melanoma samples, patients 
with high PRL1 mRNA expression had significantly decreased survival (n=53, median 
survival=72.8 months) compared with those with low PRL1 mRNA expression in the 
melanoma (n=57, median survival=362.3 months), with a hazard ratio (HR) of 0.46 (95% CI 
of ratio=0.24 to 0.88, p=0.019) (Figure 5C). These clinical data suggest that inhibition of 
PRL1 could be beneficial for melanoma treatment. Thus we hypothesized that the PRL1 
detrimerizer Cmpd-43 may exhibit anti-melanoma activity, possibly via downregulating the 
activity of both ERK1/2 and Akt pathways. To directly test this hypothesis, we examined 
whether Cmpd-43 could suppress human melanoma MeWo cell growth and motility. As 
shown in Figure 5D, Cmpd-43 dose-dependently decreased MeWo cell proliferation as 
measured by the MTT assay. Live-cell tracking was used to measure the motility of MeWo 
cells in the presence of Cmpd-43. As shown in Figure 5E, the total distance traveled over 6 
hours for Cmpd-43 treated MeWo cells was significantly less than that of the control cells. 
To determine whether Cmpd-43 preferentially inhibits cancer cell growth, we treated both 
mammary carcinoma cell line MCF7 and normal mammary epithelial cell line MCF10A 
with Cmpd-43. As observed with MeWo cells, Cmpd-43 dose-dependently suppressed the 
growth of MCF7 breast cancer cells, but the inhibitory effect of Cmpd-43 was significantly 
compromised towards non-tumorigenic MCF10A cells (Supplemental Figure 2A). In 
addition, the anti-proliferative activity of Cmpd-43 to MEF cells was also significantly 
reduced when compared to the MeWo cells (Supplemental Figure 2B). These data indicate 
that Cmpd-43 displays significantly lower cell toxicity toward normal cells.
Importantly, Cmpd-43 treatment dose-dependently reduced HGF-induced ERK1/2 and Akt 
phosphorylation (Figure 5F). To make certain that the effect of Cmpd-43 in MeWo cells is 
also mediated by blocking PRL1 trimerization, we overexpressed either wild-type PRL1 or 
the trimerization deficient mutant PRL1/G97R mutant in MeWo cells. Similar to what we 
observed in HEK293 cells (Figure 3E), we found that overexpression of PRL1 but not 
PRL1/G97R significantly enhanced both ERK1/2 and Akt phosphorylation by about ∼2 fold 
(Figure 5G). More importantly, Cmpd-43 but not Analog-1 suppressed PRL1-induced 
ERK1/2 and Akt activation. However, neither Cmpd-43 nor Analog-1 were able to reduce 
pERK1/2 and pAkt levels in PRL1/G97R expressing MeWo cells (Figure 5G), suggesting 
that Cmpd-43 inhibits PRL1-induced ERK1/2 and Akt activation in MeWo cells by blocking 
PRL1 trimerization.
The PRL1 crystal structure revealed that residues at the trimer interface are conserved 
among all three PRLs (44, Supplemental Figure 3A). We previously showed that like PRL1, 
PRL3 could also form trimer in solution and inside the cells (8, 44). Amino acid sequence 
alignment shows that key residues involved in Analog-3 binding are also highly conserved 
among all three PRLs (Supplemental Figure 3A). Therefore, we hypothesized that 
trimerization is a general property for all PRLs and Cmpd-43 should inhibit trimerization of 
all PRLs. Indeed, both PRL2 and PRL3 can form trimer, and Cmpd-43 but not Analog-1 
significantly reduces PRL2 and PRL3 trimer formation (Supplemental Figure 3B).
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To further validate the specificity of Cmpd-43 for PRLs in MeWo cells, we knocked down 
both PRL1 and PRL2, which are the major PRL isoforms expressed in MeWo cells. We first 
demonstrated that knocking down both PRL1 and PRL2 significantly reduced ERK1/2 and 
Akt activation in MeWo cells (Supplemental Figure 4). In addition, the dose-dependent 
inhibition of both pERK1/2 and pAkt by Cmpd-43 in scramble siRNA treated MeWo cells 
was significantly compromised in PRL1 and PRL2 knocked down cells (Figure 5H&I). 
These data suggest that Cmpd-43 inhibits both ERK1/2 and Akt signaling pathways in 
MeWo cells specifically through targeting both PRL1 and PRL2. Overall, these results 
demonstrate that pharmacologic inhibition of PRL trimerization in MeWo cells attenuates 
both the ERK1/2 and Akt pathway activation and inhibits cell proliferation and motility.
Given the promising activity of Cmpd-43 in cell-based assays, we next aimed to establish 
the therapeutic potential of targeting PRL with Cmpd-43. First, we characterized the 
pharmacokinetic properties of Cmpd-43 in mice. Cmpd-43 displayed a very respectable 
pharmacokinetic profile in mouse with a plasma compound exposure Cmax=0.3 μM and a 
half-life t1/2=15.8 h at a single 20 mg/kg intraperitoneal dosage. We then assessed the effect 
of Cmpd-43 on in vivo tumor growth in a mouse xenograft model using MeWo cells 
subcutaneously implanted into immunodeficient NSG mice. Once the tumor volume reached 
200 mm3, we started daily intraperitoneal injection of either vehicle control or 30 mg/kg 
Cmpd-43 and monitored the tumor growth for 3 weeks. Mice treated with Cmpd-43 
displayed reduced tumor growth throughout the experiment compared with mice treated 
with vehicle control (Figure 6A). At 21 days post treatment, we collected the tumors 
(Supplemental Figure 5), and observed a ∼62% shrinkage in tumor volume and ∼48% 
reduction in tumor weight (Figure 6A&B). Dissection and histological analyses revealed no 
apparent toxicity in major organs when the mice were treated with Cmpd-43 at 30 mg/kg 
(Supplemental Figure 6A&B). Furthermore, biochemical studies performed in samples 
isolated from the melanoma tumors revealed substantial reduction in both ERK1/2 and Akt 
phosphorylation, upon treatment with Cmpd-43 (Figure 6C). Immunohistological analyses 
of tumor tissues revealed significantly reduced proliferation and increased apoptosis in 
Cmpd-43 treated MeWo tumors (Figure 6D). Taken together, the reduction in tumor growth 
correlated with a decrease in ERK1/2 and Akt activity, validating the on-target activities of 
Cmpd-43.
In summary, recent studies expose an oncogenic role of PRLs in many cancers (3-6), raising 
the possibility that inhibition of these phosphatases might have broader therapeutic 
applications in oncology. Interestingly, the oncogenic potential of PRLs is always associated 
with their overexpression, which should increase the propensity of PRL trimerization inside 
the cell. Given the functional requirement of PRL trimerization, pharmacologic disruption of 
PRL trimerization represents an innovative approach for the treatment of human cancers 
with elevated PRL expression. By targeting the unique, noncatalytic trimerization interfaces 
that are unrelated to any other member of the PTP family, such PRL detrimerizers would be 
highly specific to the PRL. Starting from a sequential structure-based virtual screening 
strategy, we have identified Cmpd-43 and several analogs that are capable of preventing PRL 
trimerization. Biochemical and structural analyses demonstrate that Cmpd-43 and its close 
analogs directly bind the PRL1 trimer interface and obstruct PRL1 trimerization. Cmpd-43 
also specifically blocks the PRL-induced cell proliferation and migration through attenuation 
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of both ERK1/2 and Akt activity. Importantly, Cmpd-43 exhibits excellent anti-cancer 
activity both in vitro and in a xenograft mouse model of melanoma. The results not only 
further validate the importance of trimerization for PRL function but also support the clinical 
potential of compounds that inhibit PRL trimerization. Although additional medicinal 
chemistry optimization is required, these PRL detrimerizers represent valuable tools for 
elucidating PRL signaling and for developing novel agents for cancer therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification of small molecules disrupting PRL1 trimerization
A. The representation of PRL1 trimer arrangement and the two interfaces, namely BA 
(purple, residues K125, Y126, E127, D128, V130, Q131, F132, R134, Q135, K136, R138, 
G139, L146, and E150) and BC (blue, residues E11, V12, T13, Y14, K15, N16, M17, R18, 
E36, K39, Y40, G41, F92, R93, P96, G97, C98, K136, and F160) interface within monomer 
B, which were defined as two separate docking sites in the virtual screening. The active site 
pocket is highlighted in red (residues C104VAGLGR110), and the distances between each 
dimer interface and the catalytic Cys104 are indicated by dash lines. B. The overall strategy 
to identify PRL1 trimer disruptor. C. Chemical structures of the top three hits from cross-
linking assay. D. Effect of compounds 3, 26 and 43 on PRL1 trimerization inside the cells. 
E. Cmpd-43 inhibited PRL1 mediated cell proliferation. F. Cmpd-43 (10 μM) delayed the 
wound closure induced by PRL1 overexpression in HEK293 cells. Upper panel: 
representative microscopic images at different time (magnification, x100). Lower panel: 
quantification of the wound healing assay by measuring the relative wound closure. #p<0.05 
(Student's t test) compared with control group; *p<0.05 (Student's t test) compared with 
PRL1 overexpressing HEK293 cells. Data represent mean (SD) of 3 independent 
experiments.
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Figure 2. Structure and activity analysis of Cmpd-43 and its analogs
A. Chemical structures of Cmpd-43 and its analogs. B. The relative proliferation rate of 
PRL1 overexpressing cells treated with 10 μM of Cmpd-43 and its analogs. C. The relative 
migration rate of PRL1 overexpressing cells pretreated with 10 μM of Cmpd-43 and its 
analogs. #p<0.05 (Student's t test) compared with the control group; *p<0.05 (Student's t 
test) compared with PRL1 overexpressing HEK293 cells. Data represent mean (SD) value 
from 3 independent experiments.
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Figure 3. Specific inhibition of PRL1-mediated signaling, cell proliferation and migration by 
Cmpd-43
A. Cmpd-43, but not its inactive Analog-1, blocked PRL1 trimerization in HEK293 cells. B. 
PRL1/G97R has impaired trimer formation compared to wild-type PRL1. In vitro cross-
linking assay was performed by incubating recombinant PRL1 or PRL1/G97R with 0.005% 
glutaraldehyde for either 10 min at RT (Condition 1) or 30 min on ice (Condition 2). C. 
Cmpd-43 specifically and dose-dependently suppressed the cell viability of wild-type PRL1 
overexpressing HEK293 cells. D. Cmpd-43 (10 μM) specifically inhibited the migration of 
wild-type PRL1 overexpressing HEK293 cells. E. Cmpd-43 (5 μM) specifically inhibited 
PRL1 mediated ERK1/2 and Akt activation in HEK293 cells. #p<0.05 (Student's t test) 
compared with control group; *p<0.05 (Student's t test) compared with PRL1 
overexpressing HEK293 cells. Data represent mean (SD) value from 3 independent 
experiments.
Bai et al. Page 16
Cancer Res. Author manuscript; available in PMC 2017 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Analog-3 and Cmpd-43 bind to the PRL1 trimer interfaces and block PRL1 
trimerization
A. The overall structure of PRL1•Analog-3. The PRL1 is shown in ribbon with secondary 
structure labeled. Analog-3 and the catalytic Cys104 are shown in stick. Unbiased Fo-Fc 
omit map of Analog-3 contoured at +2.5s is shown in green mesh. B. Analog-3 binds to an 
area at the backside of PRL1 active site, with the majority contact area in BC-interface and 
the minority in BA-interface. C. The close-view of Analog-3 binding with PRL1. Analog-3 
and the residues within 5 Å distance of Analog-3 are shown in stick, with carbon atom 
colored in yellow and gray respectively. Two polar interactions are indicated by yellow dash 
lines. D. Effect of 20 μM Cmpd-43 on PRL1/Y14A and PRL1/F132A trimerization by in 
vitro cross-linking assay. E. The relative migration rate of PRL1/Y14A and PRL1/F132A in 
the presence of 10 μM Cmpd-43. *p<0.05 (Student's t test) compared with wild-type PRL1 
with Cmpd-43 treatment group. Data represent mean (SD) value of 3 independent 
experiments.
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Figure 5. Cmpd-43 exhibits anti-cancer activity towards melanoma cell line MeWo
A and B. Differential expression of PRL1 (A) or PRL2 (B) mRNA between normal skin 
samples (n=141) and melanoma patient samples (n=302). C. Kaplan-Meier survival analysis 
of 110 melanoma patients, grouped by their status of PRL1 mRNA expression level. D. 
Cmpd-43 does-dependently suppressed MeWo cell proliferation. E. Cmpd-43 significantly 
reduced MeWo cell motility. Total distance is the average of full track length of more than 
600 cells over 6 h. F. Cmpd-43 dose-dependently inhibited the HGF-induced ERK1/2 and 
Akt activation in MeWo cells. G. Cmpd-43 (2.5 μM) suppressed PRL1-overexpression 
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induced ERK1/2 and Akt activation. H. The inhibitory effect of Cmpd-43 towards HGF-
induced ERK1/2 and Akt activation was significantly compromised in MeWo cells treated 
with siRNAs for both PRL1 and PRL2. I. The quantification of ERK1/2 and Akt activation 
in MeWo cells treated with either scramble siRNA or siRNAs for both PRL1 and PRL2. 
*p<0.05 (Student's t test) compared with DMSO control group. Data are representative of 
three independent experiments (mean and SD).
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Figure 6. Cmpd-43 suppresses melanoma xenograft growth in vivo
A. The tumor volume of MeWo xenograft treated with either vehicle control or Cmpd-43 for 
21 days. B. The final tumor weight of MeWo xenograft at 21 days. C. Cmpd-43 treatment 
inhibited both ERK1/2 and Akt activation in MeWo xenograft tumors. Numbers from 1 to12 
indicate different tumor samples either from DMSO group (1-6) or Cmpd-43 treatment 
group (7-12). D. Cmpd-43 treatment significantly reduced proliferation and enhanced 
apoptosis in MeWo xenograft tumors. *p<0.05 (Student's t test) and *** p<0.001 (Student's t 
test) compared with control group.
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Table 1
Data collection and refinement statistics
Crystal parameters PRL1•Analog-3
Space group C2221
Cell Dimensions
 a (Å) 47.07
 b (Å) 76.47
 c (Å) 86.87
Data Collection
 resolution range (Å) 50.0 – 1.84
 no. of unique reflections 13768
 completeness (%) 98.0
 redundancy 5.7
 Rmerge a 0.113
Refinement
 resolution range (Å) 50.0 – 1.90
 no. of reflections used 11091
 completeness (%) 87.2
 no. of protein atoms 1230
 no. of inhibitors 1
 no. of ions 2
 no. of waters 102
 Rwork b/Rfree c 19.48/23.94
 RMSD bond length (Å) 0.007
 RMSD bond angle (°) 1.23
aRmerge = ΣhΣi|I(h)i − 〈I(h)〉 |/ΣhΣiI(h)i.
bRwork = Σh|F(h)calcd − F(h)obsd|/ΣhF(h)obsd, where F(h)calcd and F(h)obsd were the refined calculated and observed structure factors, 
respectively.
cRfree was calculated for a randomly selected 3.6% of the reflections that was omitted from refinement.
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